Imugene Ltd's (ASX:IMU) Leslie Chong speaks to Proactive's Andrew Scott following the news it's received a second Human Research Ethics Committee approval to begin a phase-I clinical trial of its cancer checkpoint immunotherapy candidate, PD1-Vaxx. Ethics approval is confirmation that Imugene has completed all necessary pre-clinical safety and efficacy testing of PD1-Vaxx required to begin human clinical trials.
Imugene gets green light to start phase-1 clinical trial of new cancer immunotherapy PD-1 Vaxx
Quick facts: Imugene Ltd
Price: 0.056 AUD
Market Cap: $246.88 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE